Torrent Pharmaceuticals Ltd (TORNTPHARM) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- Torrent Pharma continued to demonstrate robust performance in its branded markets, which constituted 73% of the overall revenue for the quarter.
- The two largest branded markets, India and Brazil, each delivered healthy double-digit growth, with India growing at 12% and Brazil at 21% (13% in constant currency).
- The U.S. generics business showed strong growth of 26%, driven by new launches achieving target market share and increased purchase volumes on existing contracts.
- Operating EBITDA grew by 15% to INR 1,083 crores, with an operating EBITDA margin of 32.8%, reflecting efficient operations and strong revenue growth.
- The company's overall leverage, measured by net debt to EBITDA, improved to 0.45X, indicating a healthy financial position.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.